成果報告書詳細
管理番号20130000000282
タイトル*平成24年度中間年報 「ヒトiPS細胞等幹細胞を用いた創薬スクリーニングシステムの開発」(三菱化学メディエンス株式会社、学校法人慶應義塾、国立大学法人東京医科歯科大学)
公開日2014/8/20
報告書年度2012 - 2012
委託先名三菱化学メディエンス株式会社 学校法人慶應義塾 国立大学法人東京医科歯科大学
プロジェクト番号P08030
部署名バイオテクノロジー・医療技術部
和文要約
英文要約Title: Development of Safety Pharmacology Screening System by Using Stem Cells such as iPS Cells(FY2008-FY2013)FY2012 Annual Report

This report shows results of research and development activities of the project in the fiscal 2012 year. The fourth year for the project is progressing and new facts from each research subject are emerging.In this year, high-purification methods of differentiated cardiomyocytes have been established using metabolomics analysis and we successfully isolated in both undifferentiated iPS cells and the other specialization cells from the differentiated cardiomyocytes. It was shown that the electrophysiological analysis using the multielectrode-arrays system of the cardiomyocytes from iPS cells of hereditary QT prolongation syndrome patients type I and III were effective in drug development.In development of in vitro safety pharmacological cardiotoxity system, the utilization prototype machine which added the intercellular conduction measurement function to the 2nd generation system in the last fiscal year was made as an experiment. And cell network chip fabrication and an assessment system were made as an experiment, and development of the evaluation technology for quality control of a cell chip required for utilization was promoted. According to improvement of an equipment system (hardware), development of integrated-analysis software, an analysis algorithm, and the analysis algorithm of a follow-up risk assessment system was furthered. Furthermore, the accuracy of the detection and the judgment in a known drug was examined using a 2nd generation of improvement system, and analysis software about "the abnormalities in cellular potential", "the abnormalities in intercellular conduction", and "the abnormalities in generating tension" in the commercial human iPS cell cardiomyocytes. Moreover, using the commercial human iPS cell origin cardiac muscle cell containing a disease iPS cell, the possibility of evaluation of a clinical level (Phase 1 level) and the quality evaluation of the specialization cardiac muscle cell were also promoted succeedingly, and turned a fixed quantity of necessary conditions of the optimal cell for an equipment system. Technical introduction was performed to the mega-Pharma company through the international evaluation organization HESI, and the international evaluation of the 2nd generation technology which turns into high-end model technology of this project development as a management committee of an international workshop was promoted.In addition, maintenance was advanced for the open lab for a user forum company to perform practical use and evaluation for development system, the experiment protocol for carrying out validation created, and it established the validation organization to be carried out in the fiscal 2013 year.
ダウンロード成果報告書データベース(ユーザ登録必須)から、ダウンロードしてください。

▲トップに戻る